Vicarious Surgical reports Q1 EPS ($2.58), consensus ($2.48)

“Following years of meticulous work to develop and advance our surgical system and proprietary decoupled actuating technology, we are just a few quarters away from our biggest milestone yet – our first clinical patients. 2025 will be the year Vicarious Surgical (RBOT) evolves into a clinical-stage company and demonstrates the immense value of our single-port surgical system,” said Adam Sachs, Co-Founder and Chief Executive Officer. “We are more excited than ever to direct our efforts towards the precise and timely execution of the essential steps for success in the clinic. In the first quarter, this included crucial procurement and manufacturing build efforts, which our team successfully advanced. We look forward to providing updates on our progress over the coming months.”